Exhaled breath to screen for malignant pleural mesothelioma: a validation study

Malignant pleural mesothelioma (MPM) is predominantly caused by asbestos exposure and has a poor prognosis. Breath contains volatile organic compounds (VOCs) and can be explored as an early detection tool. Previously, we used multicapillary column/ion mobility spectrometry (MCC/IMS) to discriminate between patients with MPM and asymptomatic high-risk persons with a high rate of accuracy. Here, we aim to validate these findings in different control groups.Breath and background samples were obtained from 52 patients with MPM, 52 healthy controls without asbestos exposure (HC), 59 asymptomatic former asbestos workers (AEx), 41 patients with benign asbestos-related diseases (ARD), 70 patients with benign non-asbestos-related lung diseases (BLD) and 56 patients with lung cancer (LC).After background correction, logistic lasso regression and receiver operating characteristic (ROC) analysis, the MPM group was discriminated from the HC, AEx, ARD, BLD and LC groups with 65%, 88%, 82%, 80% and 72% accuracy, respectively. Combining AEx and ARD patients resulted in 94% sensitivity and 96% negative predictive value (NPV). The most important VOCs selected were P1, P3, P7, P9, P21 and P26.We discriminated MPM patients from at-risk subjects with great accuracy. The high sensitivity and NPV allow breath analysis to be used as a screening tool for ruling out MPM.

Download Full-text

Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS)

Journal of Breath Research ◽

10.1088/1752-7155/10/4/046001 ◽

2016 ◽

Vol 10 (4) ◽

pp. 046001 ◽

Cited By ~ 10

Author(s):

Kevin Lamote ◽

Matthijs Vynck ◽

Joris Van Cleemput ◽

Olivier Thas ◽

Kristiaan Nackaerts ◽

...

Keyword(s):

Malignant Pleural Mesothelioma ◽

Ion Mobility Spectrometry ◽

Ion Mobility ◽

Pleural Mesothelioma ◽

Exhaled Breath ◽

Multicapillary Column

Download Full-text

Identification of Redox-Sensitive Transcription Factors as Markers of Malignant Pleural Mesothelioma

Cancers ◽

10.3390/cancers13051138 ◽

2021 ◽

Vol 13 (5) ◽

pp. 1138

Author(s):

Martina Schiavello ◽

Elena Gazzano ◽

Loredana Bergandi ◽

Francesca Silvagno ◽

Roberta Libener ◽

...

Keyword(s):

Oxidative Stress ◽

Transcription Factors ◽

Malignant Pleural Mesothelioma ◽

Antioxidant Defense ◽

Asbestos Exposure ◽

Predictive Biomarkers ◽

Antioxidant Systems ◽

Pleural Mesothelioma ◽

Related Factor ◽

Aggressive Cancer

Although asbestos has been banned in most countries around the world, malignant pleural mesothelioma (MPM) is a current problem. MPM is an aggressive tumor with a poor prognosis, so it is crucial to identify new markers in the preventive field. Asbestos exposure induces oxidative stress and its carcinogenesis has been linked to a strong oxidative damage, event counteracted by antioxidant systems at the pulmonary level. The present study has been focused on some redox-sensitive transcription factors that regulate cellular antioxidant defense and are overexpressed in many tumors, such as Nrf2 (Nuclear factor erythroid 2-related factor 2), Ref-1 (Redox effector factor 1), and FOXM1 (Forkhead box protein M1). The research was performed in human mesothelial and MPM cells. Our results have clearly demonstrated an overexpression of Nrf2, Ref-1, and FOXM1 in mesothelioma towards mesothelium, and a consequent activation of downstream genes controlled by these factors, which in turn regulates antioxidant defense. This event is mediated by oxidative free radicals produced when mesothelial cells are exposed to asbestos fibers. We observed an increased expression of Nrf2, Ref-1, and FOXM1 towards untreated cells, confirming asbestos as the mediator of oxidative stress evoked at the mesothelium level. These factors can therefore be considered predictive biomarkers of MPM and potential pharmacological targets in the treatment of this aggressive cancer.

Download Full-text

Increased Standardised Incidence Ratio of Malignant Pleural Mesothelioma in Taiwanese Asbestos Workers: A 29-Year Retrospective Cohort Study

BioMed Research International ◽

10.1155/2015/678598 ◽

2015 ◽

Vol 2015 ◽

pp. 1-10 ◽

Cited By ~ 1

Author(s):

Cheng-Kuan Lin ◽

Yu-Ying Chang ◽

Jung-Der Wang ◽

Lukas Jyuhn-Hsiarn Lee

Keyword(s):

Cohort Study ◽

General Population ◽

Incidence Rate ◽

Malignant Pleural Mesothelioma ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Asbestos Exposure ◽

Pleural Mesothelioma ◽

Calendar Period ◽

Incident Cases

Objective. This paper aimed to determine the standardised incidence ratio (SIR) of malignant pleural mesothelioma (MPM) in workers exposed to asbestos in Taiwan.Methods. All workers employed in asbestos-related factories and registered by the Bureau of Labour Insurance between 1 March, 1950, and 31 December, 1989, were included in the study and were followed from 1 January, 1980, through 31 December, 2009. Incident cases of all cancers, including MPM (ICD-9 code: 163), were obtained from the Taiwan Cancer Registry. SIRs were calculated based on comparison with the incidence rate of the general population of Taiwan and adjusted for age, calendar period, sex, and duration of employment.Results. The highest SIR of MPM was found for male workers first employed before 1979, with a time since first employment more than 30 years (SIR 4.52, 95% CI: 2.25–8.09). After consideration of duration of employment, the SIR for male MPM was 5.78 (95% CI: 1.19–16.89) for the workers employed for more than 20 years in asbestos-related factories.Conclusions. This study corroborates the association between occupational asbestos exposure and MPM. The highest risk of MPM was found among male asbestos workers employed before 1979 and working for more than 20 years in asbestos-related factories.

Download Full-text

Detection of isoprene traces in exhaled breath by using photonic crystals as a biomarker for chronic liver fibrosis disease

10.21203/rs.3.rs-443784/v1 ◽

2021 ◽

Author(s):

Ahmed Mehaney ◽

Hussein A. Elsayed ◽

Ashour M. Ahmed

Keyword(s):

Liver Fibrosis ◽

Photonic Crystals ◽

High Sensitivity ◽

Dielectric Materials ◽

Exhaled Breath ◽

Air Cavity ◽

One Dimensional ◽

Sensor Structure ◽

Volatile Organic ◽

First Time

Abstract Detection of blood-carried volatile organic compounds (VOCs) existing in the exhaled breath of human is an attractive research point for noninvasive diagnosis of diseases. In this research, we introduce a novel application of photonic crystals (PCs) for the detection of isoprene traces in the exhaled breath as a biomarker for liver fibrosis. This idea is introduced for the first time according to the best of our knowledge. The proposed sensor structure is a one-dimensional (1D) PC constructed from a multilayer stack of two dielectric materials covered with an air cavity layer filled with the dry exhaled breath (DEB) and a thin metallic layer of Au is attached on the top surface. Hence, the proposed sensor is configured as, [prism/Au/air cavity/(GaN/SiO2)10]. The transfer matrix method and the Drude model are adopted to calculate the numerical simulations and reflection spectra of the design. The essential key for sensing isoprene levels is the resonant optical Tamm plasmon (TP) states within the photonic bandgap. The obtained numerical results are promising such as high sensitivity (S) of 0.321 nm/ppm or 278720 nm/RIU. This technique can be reducing the risk of infection during the taking of blood samples by syringe. Also, it can prevent the pain of patients. Finally, this work opens the door for the detection of many diseases by analyzing the breaths of patients based on photonic crystals.

Download Full-text

Pleural Plaques and Malignant Pleural Mesothelioma in a Patient With Previous Asbestos Exposure

Pleural Diseases ◽

10.1016/b978-0-323-79541-8.00002-3 ◽

2022 ◽

pp. 15-22

Author(s):

Marchetti Giampietro ◽

Sorino Claudio ◽

Feller-Kopman David

Keyword(s):

Malignant Pleural Mesothelioma ◽

Asbestos Exposure ◽

Pleural Mesothelioma ◽

Pleural Plaques

Download Full-text

Case 13.8

Mayo Clinic Body MRI Case Review ◽

10.1093/med/9780199915705.003.0332 ◽

2014 ◽

pp. 628-629

Author(s):

Christine U. Lee ◽

James F. Glockner

Keyword(s):

Malignant Pleural Mesothelioma ◽

Asbestos Exposure ◽

The United States ◽

Extrapleural Pneumonectomy ◽

Parietal Pleura ◽

Pleural Mesothelioma ◽

Pleural Plaques ◽

Abnormal Chest ◽

Left Pleura ◽

Histologic Subtypes

62-year-old man with shortness of breath and an abnormal chest CT Axial 3D SPGR postgadolinium images (Figure 13.8.1) demonstrate diffuse thickening and enhancement of the left pleura, with a few minimally enhancing, focal right-sided pleural plaques. Malignant pleural mesothelioma Malignant pleural mesothelioma is a rare neoplasm that originates from the mesothelial cells lining the visceral and parietal pleura. The incidence of malignant pleural mesothelioma in the United States is 15 cases per million; there is a strong correlation with asbestos exposure. Malignant pleural mesothelioma is divided into 3 histologic subtypes: epithelial (55%-65%), sarcomatoid (10%-15%), and mixed (20%-35%). Patients with epithelial malignant pleural mesothelioma have the best prognosis, and among those with limited disease who undergo extrapleural pneumonectomy (removal of the pleura, lung, hemidiaphragm, and part of the pericardium), survival is longer (5-year survival, 39%) than among all patients (median survival, 8-18 months after diagnosis)....

Download Full-text

Multimodality treatment of malignant pleural mesothelioma

F1000Research ◽

10.12688/f1000research.15796.1 ◽

2018 ◽

Vol 7 ◽

pp. 1681 ◽

Cited By ~ 6

Author(s):

Lawek Berzenji ◽

Paul Van Schil

Keyword(s):

Malignant Pleural Mesothelioma ◽

Asbestos Exposure ◽

Multimodality Treatment ◽

Treatment Modalities ◽

Surgical Approaches ◽

Extrapleural Pneumonectomy ◽

Pleural Mesothelioma ◽

Treatment Approaches ◽

Definitive Answer ◽

Platinum Based Chemotherapy

Malignant pleural mesothelioma (MPM) is a rare disease of the pleura and is largely related to asbestos exposure. Despite recent advancements in technologies and a greater understanding of the disease, the prognosis of MPM remains poor; the median overall survival rate is about 6 to 9 months in untreated patients. The main therapeutic strategies for MPM are surgery, chemotherapy, and radiation therapy (RT). The two main surgical approaches for MPM are extrapleural pneumonectomy (EPP), in which the lung is removed en bloc, and pleurectomy/decortication, in which the lung stays in situ. Chemotherapy usually consists of a platinum-based chemotherapy, such as cisplatin, often combined with a folate antimetabolite, such as pemetrexed. More recently, immunotherapy has emerged as a possible therapeutic strategy for MPM. Evidence suggests that single-modality treatments are not an effective therapeutic approach for MPM. Therefore, researchers have started to explore different multimodality treatment approaches, in which often combinations of surgery, chemotherapy, immunotherapy, and RT are investigated. There is still no definitive answer to the question of which multimodality treatment combinations are most effective in improving the poor prognosis of MPM. Research into the effects of trimodality treatment approaches have found that radical approaches such as EPP and hemithoracic RT post-EPP are less effective than was previously assumed. In general, there are still a great number of unanswered questions and unknown factors regarding the ideal treatment approach for MPM. Hopefully, more research into multimodality therapy will provide insight into which combination of treatment modalities is most effective.

Download Full-text

Treatment of malignant pleural mesothelioma: current status and future directions

Monaldi Archives for Chest Disease ◽

10.4081/monaldi.2010.302 ◽

2016 ◽

Vol 73 (2) ◽

Author(s):

X. Dhalluin ◽

A. Scherpereel

Keyword(s):

Malignant Pleural Mesothelioma ◽

European Society ◽

Poor Prognosis ◽

Asbestos Exposure ◽

Therapeutic Strategies ◽

Current Status ◽

Pleural Mesothelioma ◽

European Respiratory Society ◽

Future Directions ◽

Cell Therapies

Previously considered to be rare, malignant pleural mesothelioma (MPM) is a highly aggressive tumour that has become a very important issue over recent years due to its poor prognosis and its increasing incidence mostly linked to previous asbestos exposure. An optimal treatment for MPM is not established yet; new therapies and predictive tools are still needed in the management of this cancer. Thus the aim of this review is to provide clinicians clear and up-to-dated data on the latest therapeutic strategies for MPM patients in 2010. The guidelines recently proposed by the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS) taskforce are summarized here. The authors also briefly reviewed the future directions in MPM treatment including targeted therapies, gene or cell therapies.

Download Full-text